C. Caroti
National Cancer Research Institute
6 Papers
7 Citations
C. Caroti is an academic researcher from National Cancer Research Institute. The author has contributed to research in topics: Survival rate & Induction chemotherapy. The author has an hindex of 3, co-authored 6 publications.
Chat about Author
Papers
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)
Corrado Boni,Marcello Tiseo,Luca Boni,Elizabeth H. Baldini,F Recchia,C. Barone,F. Grossi,Domenico Germano,E. Matano,G Marini,R. Labianca,F. Di Costanzo,A Bagnulo,C Pennucci,C. Caroti,Manlio Mencoboni,F. Zanelli,Tiziana Prochilo,Mara A. Cafferata,Andrea Ardizzoni +19 more
TL;DR: Evidence of a slight survival superiority of GP-containing regimens over platinum-free N-containing chemotherapy is provided and the addition of a third chemotherapy agent (I) to a standard G-based doublet does not improve treatment outcome.
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
Alberto Sobrero,A. Guglielmi,M. Cirillo,E Recaldin,Giovanni Luca Frassineti,Carlo Aschele,A Ravaioli,P Testore,C. Caroti,L. Gallo,M. A. Pessi,Enrico Cortesi,Daniele Turci,F. Grossi,R. Labianca +14 more
TL;DR: A highly active, little toxic, inexpensive regimen of old drugs to be used as an alternative to the more expensive combinations including CPT-11 or oxaliplatin or as the basis for combination programmes with these agents.
Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC.
Andrea Ardizzoni,Marcello Tiseo,Luca Boni,Massimo Di Maio,Lucio Buffoni,Ornella Belvedere,Francesco Grossi,Vito D'Alessandro,Filippo de Marinis,Santi Barbera,C. Caroti,Adolfo Favaretto,Diego Cortinovis,Brunello Morrica,L. Tixi,Tino Ceschia,Salvatore Parisi,Umberto Ricardi,Andrea Grimaldi,L. Loreggian,Pierina Navarria,Rudolf M. Huber,Chandra P. Belani,Paal Fr Bruswig,Giorgio V. Scagliotti,Tindaro Scolaro +25 more
TL;DR: These results do not support a meaningful survival benefit with the addition of single agent taxane given concurrently to radiotherapy after platinum-based induction in locally advanced NSCLC.
4
Induction chemotherapy followed by thoracic irradiation with or without concurrent chemotherapy in locally advanced inoperable NSCLC: A randomized phase III trial
A. Ardizzzoni,Luca Boni,Tindaro Scolaro,Giovanni Selvaggi,F. De Marinis,Lucio Buffoni,Francesco Grossi,Vito D'Alessandro,Santi Barbera,C. Caroti +9 more
TL;DR: The aim of this trial was to assess whether the combination of chemotherapy (CT) and radiotherapy (RT) is standard of care in the treatment of inoperable stage III NSCLC.
3
Re: J. Alfred Witjes. A Case of Abiraterone Acetate Withdrawal. Eur Urol 2013;64:517–8
TL;DR: This paper describes two cases of AAWD response occurring without concurrent prednisone discontinuation in men with metastatic castration-resistant prostate cancer, and describes the duration and relative benefit of the response.